By IDSE News Staff
The most recent results from the SWORD studies demonstrated long-term durable efficacy and tolerability of the two-drug combination dolutegravir/rilpivirine (DTG-RPV), according to presentations made at the 25th Annual Conference of the British HIV Association in Bournemouth, United Kingdom.
The phase 3 SWORD program evaluates the efficacy, safety and tolerability of switching to DTG-RPV from a current integrase inhibitor–, non-nucleoside reverse transcriptase inhibitor